Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Alvine Pharmaceuticals Stories

2008-10-31 06:00:04

Alvine Pharmaceuticals, a biopharmaceutical company, has announced proof of concept in a Phase I trial of ALV003, an oral protease therapy in development to detoxify gluten, intended for use by patients with celiac disease. The trial results confirmed that single doses of up to 1,800mg of ALV003 were safe and tolerable in healthy volunteers. Doses at the 300mg level achieved up to a 96% reduction of gluten in a meal in the stomach at 30 minutes, and were well tolerated by patients with...